These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32753135)

  • 1. Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia-Related Bleeding and High-Output Cardiac Failure: Significant Inter-Individual Variability in the Need for Maintenance Therapy.
    Albitar HAH; Almodallal Y; Gallo De Moraes A; O'Brien E; Choby GW; Pruthi RK; Stokken JK; Kamath PS; Cajigas HR; DuBrock HM; Krowka MJ; Iyer VN
    Mayo Clin Proc; 2020 Aug; 95(8):1604-1612. PubMed ID: 32753135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers.
    Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN
    Orphanet J Rare Dis; 2019 Nov; 14(1):256. PubMed ID: 31727111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
    J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding.
    Iyer VN; Apala DR; Pannu BS; Kotecha A; Brinjikji W; Leise MD; Kamath PS; Misra S; Begna KH; Cartin-Ceba R; DuBrock HM; Krowka MJ; O'Brien EK; Pruthi RK; Schroeder DR; Swanson KL
    Mayo Clin Proc; 2018 Feb; 93(2):155-166. PubMed ID: 29395350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
    Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
    JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
    Azzopardi N; Dupuis-Girod S; Ternant D; Fargeton AE; Ginon I; Faure F; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Leguy-Seguin V; Rivière S; Corre R; Bailly S; Paintaud G
    MAbs; 2015; 7(3):630-7. PubMed ID: 25751241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
    Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
    Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.
    Huemer F; Dejaco M; Grabmer C; Melchardt T; Neureiter D; Mayer G; Egle A; Greil R; Weiss L
    Wien Klin Wochenschr; 2017 Feb; 129(3-4):141-144. PubMed ID: 27878613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia.
    Vázquez C; Gonzalez ML; Ferraris A; Bandi JC; Serra MM
    PLoS One; 2020; 15(2):e0228486. PubMed ID: 32032395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary haemorrhagic telangiectasia: to transplant or not to transplant - is there a right time for liver transplantation?
    Muller YD; Oppliger R; Breguet R; Meyer P; Rubbia-Brandt L; Petignat PA; Harr T; Dayer E; Seebach JD
    Liver Int; 2016 Dec; 36(12):1735-1740. PubMed ID: 27864873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.
    Al-Samkari H; Kasthuri RS; Parambil JG; Albitar HA; Almodallal YA; Vázquez C; Serra MM; Dupuis-Girod S; Wilsen CB; McWilliams JP; Fountain EH; Gossage JR; Weiss CR; Latif MA; Issachar A; Mei-Zahav M; Meek ME; Conrad M; Rodriguez-Lopez J; Kuter DJ; Iyer VN
    Haematologica; 2021 Aug; 106(8):2161-2169. PubMed ID: 32675221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia.
    Brinkerhoff BT; Choong NW; Treisman JS; Poetker DM
    Am J Otolaryngol; 2012; 33(3):349-51. PubMed ID: 21917353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN
    Haemophilia; 2020 Nov; 26(6):1038-1045. PubMed ID: 32432841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injection of bevacizumab and cyanoacrylate glue for hereditary hemorrhagic telangiectasia.
    Khoueir N; Borsik M; Camous D; Herman P; Verillaud B
    Laryngoscope; 2019 Oct; 129(10):2210-2215. PubMed ID: 31566760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients.
    Guilhem A; Fargeton AE; Simon AC; Duffau P; Harle JR; Lavigne C; Carette MF; Bletry O; Kaminsky P; Leguy V; Lerolle N; Roux D; Lambert M; Chinet T; Bonnet D; Dupuis-Girod S; Rivière S
    PLoS One; 2017; 12(11):e0188943. PubMed ID: 29190827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is bevacizumab effective for reducing epistaxis in hereditary hemorrhagic telangiectasia?
    Chin CJ
    Laryngoscope; 2017 Feb; 127(2):289-290. PubMed ID: 27796042
    [No Abstract]   [Full Text] [Related]  

  • 17. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
    Parambil JG; Woodard TD; Koc ON
    Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature.
    Arizmendez NP; Rudmik L; Poetker DM
    Int Forum Allergy Rhinol; 2015 Nov; 5(11):1042-7. PubMed ID: 26202958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worsening of nose bleeding heralds high cardiac output state in hereditary hemorrhagic telangiectasia.
    Khalid SK; Pershbacher J; Makan M; Barzilai B; Goodenberger D
    Am J Med; 2009 Aug; 122(8):779.e1-9. PubMed ID: 19635281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia.
    Buscarini E; Botella LM; Geisthoff U; Kjeldsen AD; Mager HJ; Pagella F; Suppressa P; Zarrabeitia R; Dupuis-Girod S; Shovlin CL;
    Orphanet J Rare Dis; 2019 Feb; 14(1):28. PubMed ID: 30717761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.